Story
Tango Therapeutics Stock Slides on Wider-Than-Expected Q2 Loss, Rising Costs

Shares of Tango Therapeutics (NASDAQ: TNGX) fell nearly 4% in midday trading Tuesday after the company posted second-quarter financial results that missed Wall Street estimates, driven by a wider net loss and sharply higher operating expenses.
Financial Results Disappoint
For the second quarter of 2026, Tango Therapeutics reported a net loss of $0.37 per share, which was wider than both the analyst consensus forecast of a $0.32 per share loss and the $0.35 per share loss recorded in the same period a year earlier. As is common for a clinical-stage biotechnology firm, the company generated no revenue during the quarter.
Investor concern appeared to focus on rising expenditures. According to the company's report, general and administrative (G&A) expenses nearly doubled year-over-year, climbing to $22.6 million from $11.3 million in Q2 2025. Tango attributed the increase primarily to higher personnel-related costs and share-based compensation.
Pipeline Progress Overlooked
AdDespite the disappointing financial figures, the company highlighted continued clinical advancement in a Form 8-K filed with the SEC. Management noted progress in the late-stage development of its vopimetostat and daraxonrasib combination therapy for pancreatic cancer. An upcoming data presentation is scheduled for the 2026 European Society for Medical Oncology (ESMO) Congress.
However, investors on Tuesday appeared to weigh the immediate financial shortfall more heavily than the long-term pipeline milestones. The selling pressure was amplified by a mildly negative broader market, with major indices like the Nasdaq and S&P 500 trading slightly lower, creating a risk-off environment that can disproportionately impact non-revenue-generating companies.
Market Context
The decline in Tango's stock appears to be driven by company-specific fundamentals rather than a broader sector trend, as no significant negative news emerged from competitors. While the stock was trading around $26.58 on Tuesday, it remains significantly above its 52-week low of $6.25.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.